 | Up a level |
Doerner, T., Schulze-Koops, H., Burmester, G. -R., Iking-Konert, C., Schmalzing, M., Engel, A., Kaestner, P., Kellner, H., Kurthen, R., Krueger, K., Rubbert-Roth, A., Schwenke, H., Peters, M. A. and Tony, H. -P. (2019). Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin. Exp. Rheumatol., 37 (6). S. 937 - 946. PISA: CLINICAL & EXPER RHEUMATOLOGY. ISSN 1593-098X
Henes, J., Saur, S., Kofler, D. M., Kedor, C., Meisner, C., Krusche, M., Koetter, I., Xenitidis, T., Schulze-Koops, H. and Feist, E. (2022). TOCILIZUMAB SIGNIFICANTLY REDUCES SERUM AMYLOID A IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER - DATA FROM THE PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TOFFIFE STUDY. Ann. Rheum. Dis., 81. S. 30 - 32. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060
Henkemeier, U., Alten, R., Bannert, B., Baraliakos, X., Behrens, F., Heldmann, F., Kiltz, U., Koehm, M., Koenig, R., Leipe, J., Mueller-Ladner, U., Rech, J., Riechers, E., Rubbert-Roth, A., Schmidt, R. E., Schulze-Koops, H., Specker, C., Tausche, A. -K, Wassenberg, S., Witt, M., Witte, T., Zernicke, J. and Burkhardt, H. (2016). Do we still need clinical studies in rheumatology? Z. Rheumatol., 75 (1). S. 4 - 11. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250
Witt, M., Grunke, M., Proft, F., Baeuerle, M., Aringer, M., Burmester, G., Chehab, G., Fiehn, C., Fischer-Betz, R., Fleck, M., Freivogel, K., Haubitz, M., Koetter, I., Lovric, S., Metzler, C., Rubberth-Roth, A., Schwarting, A., Specker, C., Tony, H-P, Unger, L., Wassenberg, S., Doerner, T. and Schulze-Koops, H. (2013). Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus, 22 (11). S. 1142 - 1150. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0962